分类: 未分类

  • 26.12.2020. 首批BioNTech-辉瑞新冠病毒疫苗将于周六(12月26日)运抵德国16个联邦州。周日,德国将启动大规模疫苗接种计划

    26.12.2020. 首批BioNTech-辉瑞新冠病毒疫苗将于周六(12月26日)运抵德国16个联邦州。周日,德国将启动大规模疫苗接种计划。

    当地时间上午11点,德国卫生部长施潘(Jens Spahn)在记者会上就此计划发表通报。

    首先,数万剂疫苗将由位于美因茨的BioNTech制药公司运送到全国27个地点。

    随后,这些疫苗将被分发到各地疫苗中心和流动作业团队。这些团队将在周日开始首批疫苗接种。

    装在小药瓶中的疫苗将用两个特制的冷冻柜运送。该疫苗需要在零下70摄氏度的温度下保存。

    哪些人将首先接种疫苗?

    该疫苗将首先供应给年龄在80岁以上的德国居民,以及承受特殊风险的医护人员。

    预计到明年3月,将有1100万至1200万剂疫苗可供使用。由于该疫苗需要接种两次,这将让550万至600万人接种上疫苗。

    尽管其他准备工作还有待批准,施潘希望能够在夏季让所有居民都能接种上新冠病毒疫苗。

    根据调查公司YouGov周五发布的一项民意调查,近三分之二的德国人表示愿意接种该疫苗。

    疫苗接种计划功效如何?

    疫苗并非是让病毒一打了之的银色子弹,德国城镇协会试图降低人们对疫苗功效的预期。

    “这是一个开始,但危险的新冠病毒带来的恐慌还没有结束,”该协会主席荣格(Burkhard Jung)接受丰克传媒集团(Funke Mediengruppe)采访时说。

    北部城市基尔的传染病医生非肯舍尔(Helmut Fickenscher)教授告诉德新社说,疫苗接种计划 “暂时不会影响(德国)的疫情”。

    他说,”因为我们需要接种疫苗的人数实在是太多了,而且在相当长的一段时间内都不会有那么多疫苗可用。”

  • 2020年12月26日,北京市召开第192场疫情防控新闻发布会。顺义区委常委、常务副区长支现伟表示,2020年12月25日以来,顺义区新增2例新冠肺炎确诊病例,支现伟通报了2例新增确诊病例详情及活动轨迹

    12月26日,北京市召开第192场疫情防控新闻发布会。顺义区委常委、常务副区长支现伟表示,2020年12月25日以来,顺义区新增2例新冠肺炎确诊病例,全区进入战时状态,迅速启动疫情防控应急预案,开展流调溯源、核酸检测、社区管控、环境消毒等工作。各属地、各部门立即行动,开展核酸检测组织筹备、设备物资准备等工作,目前正在进行重点区域大范围核酸检测。

    新增确诊病例活动轨迹公布

    支现伟通报了2例新增确诊病例详情及活动轨迹.

    确诊病例1张某某主要行程轨迹如下:

    12月10日、11日、14日至18日、21日、22日7时至19时,北京顶全便利店有限公司顺义区货运北路一店上班;

    12月12日7时至17时在家休息;17时至18时到隆华购物中心张喜庄店、张喜庄村市场购物。

    12月13日上午在家休息,10时左右到高丽营镇张喜庄村永盛嘉禾购物中心购物。

    12月19日上午在家休息,13时许到高丽营镇张喜庄村永盛嘉禾购物中心购物,14时到南法信镇西杜兰村与同乡聚会,17时返回,时长约3小时。

    12月20日上午在家休息,14时30分前往南法信镇西杜兰村同乡家做客,15时与同乡3人乘坐网约车前往后沙峪镇物美超市。

    12月23日7时至19时上班,21时到高丽营镇张喜庄村莹新堂药房买药。

    12月24日8时至13时30分在单位上班;13时30分,乘坐地铁15号线、8号线到北京顶全便利店有限公司东城王府井大街一店做核酸检测,16时左右搭乘同事车返回。18时20分到高丽营镇张喜庄村购物。

    12月25日被确定为密切接触者,在工作店内等待转运。

    确诊病例2解某某,主要行程轨迹如下:

    12月10日5时40分,从家出发乘坐地铁到北大口腔魏公村院区就诊,9时10分乘坐地铁到公司上班。

    12月11日13时15分,到火齐潮汕粥店用餐,约1个半小时。

    12月12至13日居家未外出。

    12月14日5时40分,从家出发乘坐地铁到北大口腔魏公村院区就诊,10时乘坐地铁到公司上班。

    12月15日上班,12时10分在首开广场美食城就餐。

    12月16日8时,通过滴滴打车回家,9时到包顺昌包子店。18时出现恶心、咽痛、头晕症状,自测体温36.8℃。

    12月17日、21日正常上班,下班回家之后未外出。

    12月18日在家休息。

    12月19日在家休息,期间到北京新顺北大街日用百货店、春雨超市购物。

    12月20日在家休息,期间到鑫海韵通百货一层超市购物。

    12月22日上午在家,11时在美团外卖APP叫“鱼你在一起”(北京隆华购物中心店)外卖,下午上班。

    12月23日因病请假在家,出现发热症状,14时32分步行前往顺义区医院发热门诊就诊。发热门诊建议患者留观,患者拒绝,接诊医生要求第二天再次进行核酸检测。

    12月24日请假在家,下午到区医院发热门诊做核酸检测。15时32分到义宾生活超市购物。

    12月25日5时30分,转至地坛医院。

  • 25 Dec, 2020. Boston doctor says he almost had to be INTUBATED after suffering severe allergic reaction from Moderna Covid vaccine

    A physician in Boston said he suffered one of the worst allergic reactions he’s ever experienced after receiving Moderna’s Covid-19 jab, following a string of similar cases resulting from Pfizer’s vaccine.

    Dr. Hossein Sadrzadeh, a hematology oncology fellow at Boston Medical Center, was given the drug on Christmas Eve. The health care worker, who has a severe shellfish allergy, said his heart began to race after taking the vaccine. Initially, he thought his increased heart rate was due to anxiety he had about the jab, stemming from reports of serious medical episodes occurring after people with allergies were injected with Pfizer’s coronavirus vaccine.  

    However, he soon realized that he was suffering from something far more dangerous. Within minutes, Sadrzadeh’s tongue and throat began to tingle and go numb, a reaction that he associated with his shellfish allergy. Even more concerning, his blood pressure then dipped so low that it wasn’t even detectable with a monitor. 

    Luckily, the doctor had brought his own EpiPen, which he administered on himself before hospital staff rushed him to the emergency room. He was given several medications, including steroids and Benadryl. A record of his hospital visit stated that he was admitted to the ER for “shortness of breath, dizziness, palpitations and numbness after receiving the Covid-19 vaccine.”

    By Friday morning, he said that he was feeling normal. But the doctor seemed to suggest that the episode could have been far more harrowing had he not come prepared for the worst. 

    “I feel that if I did not have my EpiPen with me, I would be intubated right now, because it was that severe,” he said, adding that it was the worst allergic reaction he had experienced since he was 11 years old. 

    The physician said he now recommends that people with allergies receive the vaccine in a hospital setting, instead of getting it from a clinic or local provider. 

    “I knew the symptoms. I had the experience. I was a physician, and I was scared to death. Imagine someone who does not have the information,” he noted. Sadrzadeh has offered Moderna a blood sample in an effort to help the firm identify what ingredient in the vaccine may have triggered the allergic reaction.

    “I really don’t want anybody to go and experience this and go through this event that I had,” he said.

    The concerning case is the first of its kind to be linked to the Moderna jab. Officials with the Food and Drug Administration and the Centers for Disease Control and Prevention are investigating at least six cases of severe allergic reactions occurring in people who took the Pfizer-BioNTech vaccine. However, it is still being determined whether an ingredient in the vaccine is responsible for the health episodes.

  • 25 Dec, 2020. Instant immunity? UK scientists test drug to prevent people exposed to Covid-19 from catching disease via rapid antibodies boost

    British scientists have started testing a new drug that they claim gives instant immunity to Covid-19 and could save many lives by being administered as emergency treatment to those exposed to coronavirus.

    “The advantage of this medicine is that it gives you immediate antibodies,” while vaccines against the coronavirus take around a month to fully kick in,” Dr Catherine Houlihan, a virologist at University College London Hospitals NHS trust (UCLH), told the Guardian. 

    The antibody therapy, which UCLH has developed together with AstraZeneca – the maker of the yet-to-be-approved British vaccine against Covid-19 – may become “an exciting addition to the arsenal of weapons being developed to fight this dreadful virus,” Houlihan said.

    It could be used in households where someone got the coronavirus, as well as in hospitals, nursing homes, universities and elsewhere to help curb major outbreaks, while the vaccination is underway around the globe.

    The scientists believe that the remedy, which is based on AstraZeneca’s AZD7442 long-acting antibody combination, should be effective if offered to someone exposed to Covid-19 in the previous eight days. The immediate protection provided by the drug is reportedly expected to last from for six months to a year.

    The trials of the therapy – which right now sounds almost too good to be true with the lockdowns in place and new strains of the virus making headlines – started earlier in December at UCLH, some other UK hospitals and at around a hundred sites abroad. Should its efficacy be proven during tests and get a green light from the British medical regulator, the drug could become available as early as in March or April.

  • DEC. 26, 2020 . In the early days of the pandemic, epidemiologists estimated that would require inoculating about two-thirds of the U.S. population.Now many of those same experts say that figure is almost certainly too low.The question of how many people must be vaccinated is of crucial importance as the world embarks on the biggest inoculation campaign in decades

    Whatever the threshold for herd immunity, public health officials face a substantial challenge.

    An early December poll from the Associated Press-NORC Center for Public Affairs Research found that 46% of American adults planned to get vaccinated while 26% would decline and 27% were still undecided.

    One group of researchers found that anti-vaccination messaging on social media has tripled since the start of the pandemic.

    A particular obstacle could be vaccinating children and teenagers, a group that has not been hit especially hard by the pandemic and for which vaccines are still being tested. But at 22% of the U.S. population, they are important to any effort to achieve herd immunity and return to normal life.

    When epidemiologists first aimed to model how many people would need to be vaccinated in order to drive the coronavirus toward extinction, they compared early transmission trends to those of other recent flu pandemics.

    They noted how the coronavirus had a longer incubation period, more asymptomatic spread and higher contagion — estimating that the pandemic would probably drag on for 18 to 24 months.

    “It likely won’t be halted until 60% to 70% of the population is immune,” said a report published by infectious-disease experts in April.

    There are two paths to immunity: becoming infected with the virus and recovering, or getting vaccinated. Neither is a guarantee.

    Based on data from clinical trials showing that the efficacy of the two authorized vaccines — from Pfizer and Moderna — is excellent but still imperfect, the threshold for herd immunity rises to around 74%.

    But experts say even that calculation is still too simple.

    “Those numbers are useful for thought experiments, but they don’t represent what’s likely to be the way we control the virus or its impacts,” said Harvard epidemiologist Marc Lipsitch. “Offering a kind of magic number requires some very strong assumptions about these vaccines.”

    Many factors can come into play. If the virus becomes even more transmissible, the threshold for herd immunity would increase.

    The targets could vary by location. In sparsely populated places where people adhere to social distancing guidelines, fewer people would have to be vaccinated to burn out the virus.

    “It’s going to be the sort of thing that we’re studying for a very long time to come,” said William Hanage, an epidemiologist at the Center for Communicable Disease Dynamics at Harvard.

    Then there are the vaccines themselves.

    They were authorized based on rapid-fire clinical trials that showed recipients were highly unlikely to develop symptoms of COVID-19 — but did not determine whether the vaccines actually prevent people from becoming infected with the virus or transmitting it.

    The degree to which the vaccines prevent transmission matters greatly in the equation for calculating herd immunity. In a bad-case scenario, the vaccines do so little to stop transmissions that herd immunity simply can’t be achieved through vaccination alone.

    “At the moment, the jury is definitely still out,” Lipsitch said. “If I had to guess, there will be a component of herd immunity — I just don’t know how dramatic it will be.”

    It could turn out that reaching herd immunity depends not only on how many people are vaccinated but also which people. Inoculating those most likely to spread it — people who live or work in close quarters, for example — may do much more to contain the pandemic than vaccinating people who live in relative seclusion.

    Given all these unknowns, Fauci brought his estimate to 85% — and has said it could be even higher.

    The costs of not achieving herd immunity are substantial. If the virus continues to circulate broadly, even some people who are vaccinated will develop COVID-19. Hospitals will continue to confront surges of the virus, depleting their resources and compromising their ability to treat heart attacks, strokes and other emergencies.

    Meanwhile, overall quality of life would continue to suffer. Schools, offices and restaurants would remain closed even for people who have been vaccinated.

    Experts say that until the virus is circulating at extraordinarily low levels — such that the risk of becoming infected is close to zero — social distancing and mask-wearing are here to stay.

    The final answer to the question of how many people need to be vaccinated won’t be known until herd immunity is actually achieved. When epidemiologists start to see the test positivity rate falling to extremely low numbers, that’s how they’ll know the campaign is working.

    But with the exception of smallpox, no virus that afflicts humans has ever been wiped out completely. Experts have been struggling with polio for decades, lately in conflict regions where vaccination campaigns have been disrupted.

    They emphasize that in the age of globalization, herd immunity must eventually take into account almost every corner of the earth — a pathogen anywhere remains a threat everywhere.

    “I think it’s extremely unlikely that we would be able to eradicate this virus,” Hanage said. “In reality, we have to accept that.”

    “However, we should be able to get to a point where we are going to be able to live without it markedly damaging our lives, without leading to surges that damage our healthcare, or large excessive mortality — and that is what we are seeking to achieve.”